Savient (SVNT) Shares Hit as BioCryst (BCRX) Gets FDA Guidance for Gout Treatment Approval
Go back to Savient (SVNT) Shares Hit as BioCryst (BCRX) Gets FDA Guidance for Gout Treatment Approval| BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) | Delayed: 9.76 +0.10 (1.04%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.66 | 52 Week High | $10.98 | |||
| Open | $9.72 | 52 Week Low | $1.63 | |||
| Day High | $9.86 | P/E | N/A | |||
| Day Low | $9.65 | EPS | $-0.68 | |||
| Volume | 262,460 | |||||
| Savient Pharmaceuticals, Inc. (AMEX: SVNT) | Delayed: 40.05 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $40.05 | 52 Week High | $24.50 | |||
| Open | $24.98 | 52 Week Low | $14.75 | |||
| Day High | $40.05 | P/E | N/A | |||
| Day Low | $40.05 | EPS | $-1.64 | |||
| Volume | 44,442 | |||||
